Invesco Ltd. has expanded its position in Delcath Systems, Inc. through the acquisition of 399,389 shares of the company’s stock. This transaction was revealed in Invesco's latest 13F filing with the Securities and Exchange Commission.
The investment is valued at $5,084,000, indicating a notable commitment from the institutional investor. This increased stake suggests Invesco's positive outlook on Delcath Systems' future performance and growth trajectory.
Such an investment from a major institutional player can signal confidence in Delcath's ongoing commercialization efforts for HEPZATO KIT and its strategic pipeline expansion into larger indications like metastatic colorectal and breast cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.